BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16413391)

  • 1. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
    Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
    ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
    Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
    Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
    Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    van der Heiden PL; Jedema I; Willemze R; Barge RM
    Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin.
    McGavin JK; Spencer CM
    Drugs; 2001; 61(9):1317-22; discussion 1323-4. PubMed ID: 11511025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
    Matsui H; Takeshita A; Naito K; Onishi K; Ono R
    Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
    [No Abstract]   [Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Giles F; Estey E; O'Brien S
    Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
    Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives.
    Sperr WR; Florian S; Hauswirth AW; Valent P
    Leuk Lymphoma; 2005 Aug; 46(8):1115-20. PubMed ID: 16085551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.